TRANSTHERA-B (02617): First Patient Dosed in Confirmatory Phase III Trial of Tinengotinib Monotherapy for Advanced Cholangiocarcinoma

Stock News04-17

TRANSTHERA-B (02617) announced that the first patient has been dosed in a confirmatory Phase III clinical study evaluating its core product, Tinengotinib (TT-00420), as a monotherapy for patients with advanced cholangiocarcinoma. This trial is a randomized, controlled, open-label, multicenter Phase III study conducted in China. It is designed to assess the efficacy and safety of Tinengotinib compared to chemotherapy in patients with surgically unresectable, advanced or metastatic intrahepatic cholangiocarcinoma. Eligible patients have experienced recurrence or progression following prior first-line systemic therapy and carry FGFR2 fusions, rearrangements, or mutations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1176775881?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-17 18:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176775881","market":"other","top_or_hot":-1,"title":"TRANSTHERA-B (02617): First Patient Dosed in Confirmatory Phase III Trial of Tinengotinib Monotherapy for Advanced Cholangiocarcinoma","media":"Stock News","content":"<p>TRANSTHERA-B (02617) announced that the first patient has been dosed in a confirmatory Phase III clinical study evaluating its core product, Tinengotinib (TT-00420), as a monotherapy for patients with advanced cholangiocarcinoma. This trial is a randomized, controlled, open-label, multicenter Phase III study conducted in China. It is designed to assess the efficacy and safety of Tinengotinib compared to chemotherapy in patients with surgically unresectable, advanced or metastatic intrahepatic cholangiocarcinoma. Eligible patients have experienced recurrence or progression following prior first-line systemic therapy and carry FGFR2 fusions, rearrangements, or mutations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TRANSTHERA-B (02617): First Patient Dosed in Confirmatory Phase III Trial of Tinengotinib Monotherapy for Advanced Cholangiocarcinoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTRANSTHERA-B (02617): First Patient Dosed in Confirmatory Phase III Trial of Tinengotinib Monotherapy for Advanced Cholangiocarcinoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-17 18:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TRANSTHERA-B (02617) announced that the first patient has been dosed in a confirmatory Phase III clinical study evaluating its core product, Tinengotinib (TT-00420), as a monotherapy for patients with advanced cholangiocarcinoma. This trial is a randomized, controlled, open-label, multicenter Phase III study conducted in China. It is designed to assess the efficacy and safety of Tinengotinib compared to chemotherapy in patients with surgically unresectable, advanced or metastatic intrahepatic cholangiocarcinoma. Eligible patients have experienced recurrence or progression following prior first-line systemic therapy and carry FGFR2 fusions, rearrangements, or mutations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1176775881","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176775881","pubTimestamp":1776422683,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"TRANSTHERA-B (02617) announced that the first patient has been dosed in a confirmatory Phase III clinical study evaluating its core product, Tinengotinib (TT-00420), as a monotherapy for patients...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK4134":"信息科技咨询与其它服务","III":"信息服务","02617":"药捷安康-B"},"translate_title":"Tranthera-B（02617）：替能替尼单药治疗晚期胆管癌的确证性III期试验中首例给药患者","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1,"III":1},"content_text":"TRANSTHERA-B (02617) announced that the first patient has been dosed in a confirmatory Phase III clinical study evaluating its core product, Tinengotinib (TT-00420), as a monotherapy for patients with advanced cholangiocarcinoma. This trial is a randomized, controlled, open-label, multicenter Phase III study conducted in China. It is designed to assess the efficacy and safety of Tinengotinib compared to chemotherapy in patients with surgically unresectable, advanced or metastatic intrahepatic cholangiocarcinoma. Eligible patients have experienced recurrence or progression following prior first-line systemic therapy and carry FGFR2 fusions, rearrangements, or mutations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1176775881","isCrawlerRequest":true}